GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers

Rasheed SAK, Leong HS, Lakshmanan M, Raju A, Dadlani D, Chong FT, Shannon NB, Rajarethinam R, Skanthakumar T, Tan EY, Hwang JSG, Lim KH, Tan DSW, Ceppi P, Wang M, Tergaonkar V, Casey PJ, Iyer NG (2017)


Publication Type: Journal article

Publication year: 2017

Journal

DOI: 10.1038/s41388-017-0038-6

Abstract

Treatment failure in solid tumors occurs due to the survival of specific subpopulations of cells that possess tumor-initiating (TIC) phenotypes. Studies have implicated G protein-coupled-receptors (GPCRs) in cancer progression and the acquisition of TIC phenotypes. Many of the implicated GPCRs signal through the G protein GNA13. In this study, we demonstrate that GNA13 is upregulated in many solid tumors and impacts survival and metastases in patients. GNA13 levels modulate drug resistance and TIC-like phenotypes in patient-derived head and neck squamous cell carcinoma (HNSCC) cells in vitro and in vivo. Blockade of GNA13 expression, or of select downstream pathways, using small-molecule inhibitors abrogates GNA13-induced TIC phenotypes, rendering cells vulnerable to standard-of-care cytotoxic therapies. Taken together, these data indicate that GNA13 expression is a potential prognostic biomarker for tumor progression, and that interfering with GNA13-induced signaling provides a novel strategy to block TICs and drug resistance in HNSCCs.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Rasheed, S.A.K., Leong, H.S., Lakshmanan, M., Raju, A., Dadlani, D., Chong, F.-T.,... Iyer, N.G. (2017). GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers. Oncogene. https://dx.doi.org/10.1038/s41388-017-0038-6

MLA:

Rasheed, Suhail Ahmed Kabeer, et al. "GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers." Oncogene (2017).

BibTeX: Download